1 / 30

Accelerating the Availability of an Artificial Pancreas Aaron J. Kowalski Ph.D. Eighth Annual Diabetes Technology Meeti

JDRF's mission has been constant since we were founded 37 years ago: find a cure for diabetes and its complications.. Our Mission. Where We've Been. 3. 4. Some Diabetes Technologies Milestones . Early days ? Ants and Urine Tasters 1921 - InsulinLate 70's ? BG and CSII1977 - BiostatorEarly 80'

tuwa
Télécharger la présentation

Accelerating the Availability of an Artificial Pancreas Aaron J. Kowalski Ph.D. Eighth Annual Diabetes Technology Meeti

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. 1

    2. JDRF’s mission has been constant since we were founded 37 years ago: find a cure for diabetes and its complications. Our Mission

    3. Where We’ve Been

    4. Some Diabetes Technologies Milestones Early days – Ants and Urine Tasters 1921 - Insulin Late 70’s – BG and CSII 1977 - Biostator Early 80’s – Recombinant Human Insulin Late 90’s - CGMS 2001 – 1st Annual DTS Meeting 2005 – First Real-Time CGM FDA Approved 2005 – JDRF APP Launch 2006 – FDA Adds Artificial Pancreas to Critical Path 20? – First System to Automatically Push Insulin

    5. Why We Need an Artificial Pancreas

    7. Hemoglobin A1c Levels are Elevated in the United States and appear to have Plateaued Reported at Diabetes Mellitus Interagency Coordinating Committee (DMICC) CDC: NHANES III – Mean A1c 7.7%, NHANES II – Mean A1c 7.6%, 60% >7.0% Kaiser: TRIAD – A1c’s have stayed the same or declined slightly over the past 10 years VA : 59% of people with diabetes in VA system are above A1c 7.0% Summary: Many factors, but tools may be suboptimal for reducing HbA1c below 7.0%

    8. The JDRF Artificial Pancreas Project 8

    9. 9 The First Generation of an Artificial Pancreas

    10. 10 APP Project Goals Accelerate the availability of a first generation artificial pancreas Ensure the artificial pancreas and its components are widely available Ensure devices from multiple companies are approved and reimbursed Create a robust and thriving market that stimulates significant industry investment in next generation technologies

    11. Multiple Steps to Improved Patient Outcomes UPDATE!!

    12. 12 JDRF Funded Research Track One: CGM Trial Track Two: Artificial Pancreas Consortium Track Three: JDRF – Company Partnerships

    13. 13 Removed line that represented Group HealthRemoved line that represented Group Health

    14. JDRF Continuous Glucose Monitor Trial

    15. JDRF Funded Artificial Pancreas Consortium Roy BeckRoy Beck

    16. Hybrid open/closed system – 1st subject

    17. Results: Increased Time in Target Range from 58 to 82%

    19. 19

    20. 20

    21. 21

    22. 22

    23. 23

    24. 24

    25. 25

    26. 26

    28. A thought in conclusion

    29. You Can Help Sign up for JDRF’s CGM advocacy campaign (www.jdrf.org/cgm) Keep up with the latest Visit www.jdrf.org/artificialpancreas, sign up for newsletter

    30. For more information See the JDRF Artificial Pancreas Project Website: www.jdrf.org/artificialpancreas Or Email me: akowalski@jdrf.org

More Related